Company*
(Country; Symbol)

Funding
Institution

Amount
(M)

Type

Details (Date)


Aureus Pharma*
(France) and
ChemAxon*

European Union

ND

European Eureka project related to hepatotoxicity, as well

The firms, along with Sanofi-Aventis and Budapest University, will build a knowledge base (Hungary) as accompanying predictive tools (5/16)

Aradigm
Corp.
(ARDM)

Defence R&D Canada

$0.663

Funding support

The extending funding will support a preclinical study of inhaled liposomal ciprofloxacin for post- exposure prophylaxis against inhalational anthrax (4/26)

Arbor Vita Corp.*
and PATH

National Cancer Institute

$0.6

Phase I SBIR grant

Arbor Vita and the nonprofit organization will use funds to develop a lateral flow test to detect precancerous cervical lesions using E6, a protein marker (6/28)

Arteriocyte
Inc.*

State of Ohio

$0.6

Grant

The grant, part of an $8M award to Cleveland's Center for Stem Cell and Regenerative Medicine, will be used in development of Arteriocyte's stem cell technology (5/19)

Athersys Inc.*

State of Ohio

$3.5

Third Frontier Program funding

Athersys is getting $3.5M of a total of $8M awarded to the Center for Stem Cell and Regenerative Medicine, which was founded by Athersys and includes a number of institutions in Ohio (5/15)

Avecia Biotechnology
Inc.*
(UK)

National Institute of Allergy and Infectious Diseases

$3.9

Grant

Funding will support Avecia's development of a version of Thraxine, a recombinant protective antigen-based anthrax vaccine, with increased stability (6/12)

AvidBiotics
Corp.*

National Institutes of Health

ND

Phase I SBIR grant

The grant will support work on development of a class of agents against plague (5/8)

BioNanomatrix
LLC*

National Cancer Institute

ND

SBIR grant

Funds will support development of the company's technology for cancer detection devices and methodologies (5/17)

Cangene Corp.
(Canada; TSE:CNJ)

Department of Health and Human Services

$362

Project BioShield contract

The five-year contract covers development and supply of 200,000 doses of botulinum toxin immune globulin; the contract requires Cangene get FDA approval of the product (5/31)

CellCentric
Ltd.*
(UK)

UK Department of Trade and Industry

£1.15 ($2.1)

Technology Program award

CellCentric and three research institutions are getting a total of £2.3M for a program in epigenetics; partners are the Gurdon Institute, the Babraham Institute and the University of Nottingham (5/4)

CombiMatrix
Group
(CBMX)

U.S. Army Research Office

$1.9

Contract

The new funding will support development of a device for detecting a variety of microorganisms within one hour (4/24)

CombiMatrix
Group
(CBMX)

The National Academies

ND

Keck Futures Initiative grant

CombiMatrix and Texas A&M University will use the funds on a method to increase the speed of hybridization in DNA microarray applications (4/11)

CombinatoRx
Inc.
(CRXX)

The Economic Development Board of Singapore

ND

Research Incentive Scheme for Companies grant

CombinatoRx's Singapore subsidiary will use the funds to support research and development in the area of infectious diseases (4/21)

Cyntellect
Inc.*

National Science Foundation

$0.5

Phase IIB SBIR grant

Funding will support development of Cyntellect's laser-based LEAP system for enhancing RNA interference applications (6/27)

CytImmune
Sciences Inc.*

National Cancer Institute

$0.5

Phase I SBIR grant

Funds will support development of the pegylated colloidal gold tumor-targeting nanotechnology product CTY-21001 (3/30)

Epeius
Biotechnologies
Corp.*

Lazarex Cancer Foundation

$0.4

Grant

Funds will support ongoing gene therapy trials of Rexin-G for treating advanced pancreatic cancer (6/19)

GammaCan
International Inc.
(Israel: OTC BB:GCAN)
and Life
Therapeutics
(Australia)

Israel-U.S. Binational Industrial Research and Development Foundation

$1

Grant

Funding will support development of VitiGam, an IgG-based immunotherapy product for treating patients with Stage III and IV melanoma (6/21)

GenVec Inc.
(GNVC)

Naval Medical Research Center

$0.5

Contract award

Funding will support work on GenVec's adenovector-based malaria vaccines; it is the third year of funding for the program (4/27)

Human
Genome
Sciences Inc.
(HGSI)

Department of Health and Human Services

$165

Project BioShield contract

Following the first phase of the contract, HHS exercised its option to purchase 20,000 courses of ABthrax, a product for preventing and treating anthrax infection (6/20)

Lexicon
Genetics Inc.
(LEXG)

U.S. Army Medical Research & Materiel Command

$2

Grant

The one-year initial term of the grant calls for Lexicon to identify targets for development of drugs to treat or prevent spinal muscular atrophy (5/11)

MedImmune
Inc.
(MEDI)

U.S. Department of Health and Human Services

$170

Contract award

Five-year award will fund work on cell- ased seasonal and pandemic vaccines that use live, attenuated, needle-free influenza vaccine technology (5/4)

Micronics Inc.*

National Cancer Institute

ND

Phase I SBIR grant

Funds will support work with the Fred Hutchinson Cancer Research Center to develop a point-of-care diagnostic system for early detection of colon cancer (4/11)

Neurodem
Ltd.*
(Israel)

The Michael J. Fox Foundation for Parkinson's Research

$0.49

Grant

Funds will support development of a transdermal patch for continuous delivery of levodopa (5/12)

Oragenics Inc.
(AMEX:ONI)

National Science Foundation

ND

Phase I SBIR grant

Research will focus on production of analogues from the class of antibiotics called lantibiotics (5/2)

Panacea
Pharmaceuticals
Inc.*

National Heart, Lung and Blood Institute

$0.88

Phase II SBIR grant

Funding will be used to complete preclinical studies of PAN-811, a neuroprotective agent being developed to treat ischemic stroke (6/21)

Peregrine
Pharmaceuticals
Inc.
(PPHM)

U.S. Department of Defense

$0.46

Grant

Collaborators at the University of Texas Southwestern Medical Center will use the funds to study Peregrine's anti-phospholipid agent bavituximab (Tarvacin) for imaging and treating recurrent breast cancer (4/25)

Pharmos
Corp.
(PARS)

Israeli Ministry of Industry and Trade

$1.3

Grant

Up to $1.3M in funding will be provided to support candidates from Pharmos' CB2- selective platform of synthetic cannabinoids (4/10)

Prothera
Biologics*

National Institutes of Health

$1.8

Phase II SBIR grant

Funding will support studies of of therapeutic proteins designed to restore the proper balance of inter-alpha inhibitor proteins for treating sepsis (6/27)

Prothera
Biologics*

National Institute of Allergy and Infectious Diseases

$1

Phase I STTR grant

Funding will support development of inter- alpha inhibitor proteins as a therapeutic for exposure to the anthrax bacterium (6/27)

Reaction
Biology Corp.*

National Cancer Institute

$0.94

SBIR grant

RBC will use the funding to migrate the current well-plate radioisotope methods onto its DiscoveryDot nanoliter screening platform (6/20)

Sirtris
Pharmaceuticals
Inc.*

The ALS Association

ND

Research grant

Funds will support research on a compound that activates sirtuins for the treatment of amyotrophic lateral sclerosis (4/21)

Solazyme Inc.*

Not disclosed

ND

Phase I STTR grant

Funds will be used to pursue genetic engineering of Dunaliella, a green eukaryotic microalgae; Solazyme will work with Brooklyn College in the project (6/21)

Starpharma
Holdings Ltd.
(Australia; ASX:SPL)

National Institute of Allergy and Infectious Diseases

ND

Funding support

The NIAID will fund a clinical trial to test VivaGel in the prevention of genital herpes; funding is in addition to $20.3M being provided to test the microbicide for the prevention of HIV (4/19)

Theratechnologies
Inc.
(Canada;
TSE:TH)

National Institute on Aging

$2.6

Grant

Funds will support a clinical trial of the company's TH9507 on cognitive function in healthy and mildly impaired older adults (3/28)


Notes:
* Indicates a privately held company.
Currency conversions reflect values at the time of a deal's announcement.
SBIR = Small Business Innovation Research; STTR = Small Business Technology Transfer.
Unless otherwise indicated, symbols listed are on the Nasdaq market.
AMEX = American Stock Exchange; ASX = Australian Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange.

No Comments